After an FDA Warning Letter: the Documented Process

Updated August 25, 2026

Every FDA warning letter in the December 10, 2024 and March 31, 2026 research-peptide batches was delivered by email, demanded a written response within 15 working days to FDAADVISORY@fda.hhs.gov, warned of seizure and injunction, and was posted publicly about a week after issuance. No close-out or follow-on action has been found for any of the eleven letters.

The mechanics, from the letters themselves

The eleven letters this index has verified across the two batches close identically. This page collects those closing mechanics in one place — what a recipient is told to do, on what clock, and to what address — as the letters themselves state them. What a warning letter is as a document is covered separately at the warning-letter reference page; this page covers the steps after signature.

The response window

Both batches give the recipient 15 working days from receipt to answer in writing, and both route that answer to a single named mailbox, FDAADVISORY@fda.hhs.gov, rather than to an individual reviewer. The clock is short relative to the review that preceded it: the December 10, 2024 letters record site reviews conducted in October 2024, and the March 31, 2026 letters record review windows running from December 2025 through March 2026 — months of observation on the agency's side, working days on the recipient's.

The escalation wording

Each letter warns that uncorrected violations can bring legal action, and the remedy language the letters name is "seizure and injunction." In the documented record of these two batches, that wording is a warning, not an event — this index has found no seizure or injunction action against any of the eleven recipients. The wording matters because it defines what the agency reserves, not what it has done.

Public posting

Posting lags signature by about a week in both batches: the December 10, 2024 letters carry a December 17, 2024 content date and surfaced in the FDA Roundup of that day, and the March 31, 2026 letters were posted April 7, 2026. From that point the letter number, recipient, and cited evidence are permanent public record, searchable by company name. All eleven letters carry the same signature block: "/S/ Tina Smith, M.S., Captain, U.S. Public Health Service, Director, Office of Unapproved Drugs and Labeling Compliance, Office of Compliance, CDER."

What is known about outcomes: nothing

Whether a recipient responded, what the response said, and whether FDA accepted it are not public at the letter stage, and this index does not infer them. A recipient that resolves the violations can eventually receive a close-out from the agency; a recipient that does not can face the escalation the letters name. As of this page's dateline, no close-out and no follow-on action has been found for any letter in either batch — not for the four recipients of the December 10, 2024 batch and not for the seven of the March 31, 2026 batch. The outcome status of all eleven letters is unknown, and each entity's entry in the vendor index records it that way.

What a close-out looks like when one does issue, and how long it took in the one case this index has documented, is recorded at what an FDA close-out letter means.

For the opposite outcome, the record to read is what turns a misbranding charge into a felony. In one case covered there, the seller was told by FDA during an inspection that he was breaking the law, shut down for a week, and then reopened under a new website — and that sequence is what the government recited as evidence of the intent that raised the offense from a one-year misdemeanor to a three-year felony.

Sources

1. FDA Warning Letters database. fda.gov
2. FDA Warning Letter, Summit Research Peptides, 695607-12102024. fda.gov
3. FDA Warning Letter, Xcel Research LLC, 694608-12102024. fda.gov
4. FDA Warning Letter, Lovega LLC dba Pink Pony Peptides, 721088-03312026. fda.gov
5. FDA Roundup, December 17, 2024. fda.gov

How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.